Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 3/20 | 0.44 |
| ▸ | FEN1 | P39748 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249309 | 0.88 | KMT2A (0.62) | KMT2AMEN1CYP3A4HPGDKDM4E | |
| SCHEMBL9352579 | 0.81 | TSHR (0.60) | TPMTKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL30552351 | 0.80 | NR4A2 (0.65) | TPMTKMT2AHPGDSMN1; SMN2CA1 | |
| SCHEMBL27745077 | 0.80 | TPMT (0.48) | TPMTKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL3860105 | 0.80 | TPMT (0.48) | TPMTKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL2715371 | 0.79 | PTPN1 (0.58) | KMT2AMEN1CYP3A4HPGDKDM4E | |
| SCHEMBL5873119 | 0.78 | GSK3B (0.61) | TPMTKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL98540 | 0.78 | KMT2A (0.80) | KMT2AMEN1CYP3A4HPGDKDM4E | |
| SCHEMBL4842224 | 0.77 | NPC1 (0.73) | KMT2AMEN1CYP3A4HPGDKDM4E | |
| SCHEMBL4716770 | 0.77 | ERCC5 (0.70) | KMT2AMEN1CYP3A4HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103189361-B | Estrogenic agents and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| US-8324401-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-7592461-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1973890-A2 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| WO-2007073503-A2 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB1, NR3C1, NR5A1 | TPMT 3929/4885KMT2A 4241/4885MEN1 3604/4885 |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | NFKB1, NR3C1, NR5A1 | TPMT 4061/4885KMT2A 4002/4885MEN1 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.